Biological reactive intermediates in drug discovery and development: a perspective from the pharmaceutical industry.
Baillie
T A
TA
Department of Drug Metabolism, Merck Research Laboratories, West Point, PA 19486, USA.
Kassahun
K
K
D001189:Aryl Hydrocarbon Hydroxylases; D002839:Chromans / Q000009:adverse effects / Q000737:chemistry / Q000378:metabolism*; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D015195:Drug Design; D005978:Glutathione / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000378:metabolism*; D010089:Oxidoreductases, N-Demethylating / Q000378:metabolism; D013844:Thiazoles / Q000009:adverse effects / Q000737:chemistry / Q000378:metabolism*; D045162:Thiazolidinediones; D000077288:Troglitazone
D002839:Chromans; D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; D003577:Cytochrome P-450 Enzyme System; D001189:Aryl Hydrocarbon Hydroxylases; D051544:Cytochrome P-450 CYP3A; D010089:Oxidoreductases, N-Demethylating; D005978:Glutathione; D000077288:Troglitazone